APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

α-Glucosidase Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global α-Glucosidase Inhibitors Market Analysis and Forecast 2026-2032

20 December 2025210 pages

Choose your research edition.

Industry Researchα-Glucosidase Inhibitors Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal α-Glucosidase Inhibitors Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal α-Glucosidase Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal α-Glucosidase Inhibitors Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal α-Glucosidase Inhibitors Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global α-Glucosidase Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for α-Glucosidase Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for α-Glucosidase Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for α-Glucosidase Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for α-Glucosidase Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of α-Glucosidase Inhibitors include Bluepharma, Glenmark Pharma, Lunan Pharma, Lupin Pharma, Strides Pharma, Bayer, Beijing SL Pharmaceutical, Cisen Pharmaceutical and Hangzhou East China Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for α-Glucosidase Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of α-Glucosidase Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for α-Glucosidase Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the α-Glucosidase Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global α-Glucosidase Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for α-Glucosidase Inhibitors sales, projected growth trends, production technology, application and end-user industry.

α-Glucosidase Inhibitors Segment by Company

Bluepharma

Glenmark Pharma

Lunan Pharma

Lupin Pharma

Strides Pharma

Bayer

Beijing SL Pharmaceutical

Cisen Pharmaceutical

Hangzhou East China Pharmaceutical

Pfizer

Jinri Pharmaceutical (China)

Livzon Pharm

Luye Pharma

Nanjing Hicin Pharmaceutical

Shandong New Time Pharmaceutical

CSPC Ouyi Pharmaceutical

Weiao Pharmaceutical (Sichuan)

Sun Pharmaceutical

SUN Pharma

Takeda

YaoPharma

Zhejiang Hisun Pharmaceutical

Zhejiang Jingxin Pharmaceutical

Zhejiang Medicine

α-Glucosidase Inhibitors Segment by Type

Acarbose

Voglibose

Miglitol

Other

α-Glucosidase Inhibitors Segment by Application

Hospital and Clinic

Pharmacy

Other

α-Glucosidase Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global α-Glucosidase Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of α-Glucosidase Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of α-Glucosidase Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of α-Glucosidase Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of α-Glucosidase Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, α-Glucosidase Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global α-Glucosidase Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Acarbose Major Manufacturers Table 3. Voglibose Major Manufacturers Table 4. Miglitol Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global α-Glucosidase Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital and Clinic Major Manufacturers Table 8. Pharmacy Major Manufacturers Table 9. Other Major Manufacturers Table 10. α-Glucosidase Inhibitors Industry Trends Table 11. α-Glucosidase Inhibitors Industry Drivers Table 12. α-Glucosidase Inhibitors Industry Opportunities and Challenges Table 13. α-Glucosidase Inhibitors Industry Restraints Table 14. Global α-Glucosidase Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global α-Glucosidase Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 16. Global α-Glucosidase Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 17. Global α-Glucosidase Inhibitors Revenue Market Share by Region (2021-2026) Table 18. Global α-Glucosidase Inhibitors Revenue Market Share by Region (2027-2032) Table 19. Global α-Glucosidase Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global α-Glucosidase Inhibitors Sales by Region (2021-2026) & (K Units) Table 21. Global α-Glucosidase Inhibitors Sales by Region (2027-2032) & (K Units) Table 22. Global α-Glucosidase Inhibitors Sales Market Share by Region (2021-2026) Table 23. Global α-Glucosidase Inhibitors Sales Market Share by Region (2027-2032) Table 24. Global α-Glucosidase Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global α-Glucosidase Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 26. Global α-Glucosidase Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global α-Glucosidase Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 28. Global α-Glucosidase Inhibitors Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global α-Glucosidase Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global α-Glucosidase Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global α-Glucosidase Inhibitors Manufacturers, Product Type & Application Table 32. Global α-Glucosidase Inhibitors Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global α-Glucosidase Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global α-Glucosidase Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global α-Glucosidase Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 37. Global α-Glucosidase Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 38. Global α-Glucosidase Inhibitors Revenue Market Share by Type (2021-2026) Table 39. Global α-Glucosidase Inhibitors Revenue Market Share by Type (2027-2032) Table 40. Global α-Glucosidase Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 42. Global α-Glucosidase Inhibitors Sales by Type (2027-2032) & (K Units) Table 43. Global α-Glucosidase Inhibitors Sales Market Share by Type (2021-2026) Table 44. Global α-Glucosidase Inhibitors Sales Market Share by Type (2027-2032) Table 45. Global α-Glucosidase Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 46. Global α-Glucosidase Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 47. Global α-Glucosidase Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global α-Glucosidase Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 49. Global α-Glucosidase Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 50. Global α-Glucosidase Inhibitors Revenue Market Share by Application (2021-2026) Table 51. Global α-Glucosidase Inhibitors Revenue Market Share by Application (2027-2032) Table 52. Global α-Glucosidase Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 54. Global α-Glucosidase Inhibitors Sales by Application (2027-2032) & (K Units) Table 55. Global α-Glucosidase Inhibitors Sales Market Share by Application (2021-2026) Table 56. Global α-Glucosidase Inhibitors Sales Market Share by Application (2027-2032) Table 57. Global α-Glucosidase Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 58. Global α-Glucosidase Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 59. Bluepharma Company Information Table 60. Bluepharma Business Overview Table 61. Bluepharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Bluepharma α-Glucosidase Inhibitors Product Portfolio Table 63. Bluepharma Recent Development Table 64. Glenmark Pharma Company Information Table 65. Glenmark Pharma Business Overview Table 66. Glenmark Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Glenmark Pharma α-Glucosidase Inhibitors Product Portfolio Table 68. Glenmark Pharma Recent Development Table 69. Lunan Pharma Company Information Table 70. Lunan Pharma Business Overview Table 71. Lunan Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Lunan Pharma α-Glucosidase Inhibitors Product Portfolio Table 73. Lunan Pharma Recent Development Table 74. Lupin Pharma Company Information Table 75. Lupin Pharma Business Overview Table 76. Lupin Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Lupin Pharma α-Glucosidase Inhibitors Product Portfolio Table 78. Lupin Pharma Recent Development Table 79. Strides Pharma Company Information Table 80. Strides Pharma Business Overview Table 81. Strides Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Strides Pharma α-Glucosidase Inhibitors Product Portfolio Table 83. Strides Pharma Recent Development Table 84. Bayer Company Information Table 85. Bayer Business Overview Table 86. Bayer α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Bayer α-Glucosidase Inhibitors Product Portfolio Table 88. Bayer Recent Development Table 89. Beijing SL Pharmaceutical Company Information Table 90. Beijing SL Pharmaceutical Business Overview Table 91. Beijing SL Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Beijing SL Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 93. Beijing SL Pharmaceutical Recent Development Table 94. Cisen Pharmaceutical Company Information Table 95. Cisen Pharmaceutical Business Overview Table 96. Cisen Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Cisen Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 98. Cisen Pharmaceutical Recent Development Table 99. Hangzhou East China Pharmaceutical Company Information Table 100. Hangzhou East China Pharmaceutical Business Overview Table 101. Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 103. Hangzhou East China Pharmaceutical Recent Development Table 104. Pfizer Company Information Table 105. Pfizer Business Overview Table 106. Pfizer α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Pfizer α-Glucosidase Inhibitors Product Portfolio Table 108. Pfizer Recent Development Table 109. Jinri Pharmaceutical (China) Company Information Table 110. Jinri Pharmaceutical (China) Business Overview Table 111. Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Product Portfolio Table 113. Jinri Pharmaceutical (China) Recent Development Table 114. Livzon Pharm Company Information Table 115. Livzon Pharm Business Overview Table 116. Livzon Pharm α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Livzon Pharm α-Glucosidase Inhibitors Product Portfolio Table 118. Livzon Pharm Recent Development Table 119. Luye Pharma Company Information Table 120. Luye Pharma Business Overview Table 121. Luye Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Luye Pharma α-Glucosidase Inhibitors Product Portfolio Table 123. Luye Pharma Recent Development Table 124. Nanjing Hicin Pharmaceutical Company Information Table 125. Nanjing Hicin Pharmaceutical Business Overview Table 126. Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 128. Nanjing Hicin Pharmaceutical Recent Development Table 129. Shandong New Time Pharmaceutical Company Information Table 130. Shandong New Time Pharmaceutical Business Overview Table 131. Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 133. Shandong New Time Pharmaceutical Recent Development Table 134. CSPC Ouyi Pharmaceutical Company Information Table 135. CSPC Ouyi Pharmaceutical Business Overview Table 136. CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 138. CSPC Ouyi Pharmaceutical Recent Development Table 139. Weiao Pharmaceutical (Sichuan) Company Information Table 140. Weiao Pharmaceutical (Sichuan) Business Overview Table 141. Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Product Portfolio Table 143. Weiao Pharmaceutical (Sichuan) Recent Development Table 144. Sun Pharmaceutical Company Information Table 145. Sun Pharmaceutical Business Overview Table 146. Sun Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Sun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 148. Sun Pharmaceutical Recent Development Table 149. SUN Pharma Company Information Table 150. SUN Pharma Business Overview Table 151. SUN Pharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. SUN Pharma α-Glucosidase Inhibitors Product Portfolio Table 153. SUN Pharma Recent Development Table 154. Takeda Company Information Table 155. Takeda Business Overview Table 156. Takeda α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Takeda α-Glucosidase Inhibitors Product Portfolio Table 158. Takeda Recent Development Table 159. YaoPharma Company Information Table 160. YaoPharma Business Overview Table 161. YaoPharma α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. YaoPharma α-Glucosidase Inhibitors Product Portfolio Table 163. YaoPharma Recent Development Table 164. Zhejiang Hisun Pharmaceutical Company Information Table 165. Zhejiang Hisun Pharmaceutical Business Overview Table 166. Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 168. Zhejiang Hisun Pharmaceutical Recent Development Table 169. Zhejiang Jingxin Pharmaceutical Company Information Table 170. Zhejiang Jingxin Pharmaceutical Business Overview Table 171. Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio Table 173. Zhejiang Jingxin Pharmaceutical Recent Development Table 174. Zhejiang Medicine Company Information Table 175. Zhejiang Medicine Business Overview Table 176. Zhejiang Medicine α-Glucosidase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Zhejiang Medicine α-Glucosidase Inhibitors Product Portfolio Table 178. Zhejiang Medicine Recent Development Table 179. North America α-Glucosidase Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 180. North America α-Glucosidase Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 181. North America α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 182. North America α-Glucosidase Inhibitors Sales by Type (2027-2032) & (K Units) Table 183. North America α-Glucosidase Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 184. North America α-Glucosidase Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 185. North America α-Glucosidase Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 186. North America α-Glucosidase Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 187. North America α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 188. North America α-Glucosidase Inhibitors Sales by Application (2027-2032) & (K Units) Table 189. North America α-Glucosidase Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 190. North America α-Glucosidase Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 191. North America α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 192. North America α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 193. North America α-Glucosidase Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 194. North America α-Glucosidase Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 195. North America α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 196. North America α-Glucosidase Inhibitors Sales by Country (2027-2032) & (K Units) Table 197. North America α-Glucosidase Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 198. North America α-Glucosidase Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 199. United States α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 200. Canada α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 201. Europe α-Glucosidase Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 202. Europe α-Glucosidase Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 203. Europe α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 204. Europe α-Glucosidase Inhibitors Sales by Type (2027-2032) & (K Units) Table 205. Europe α-Glucosidase Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 206. Europe α-Glucosidase Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 207. Europe α-Glucosidase Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 208. Europe α-Glucosidase Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 209. Europe α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 210. Europe α-Glucosidase Inhibitors Sales by Application (2027-2032) & (K Units) Table 211. Europe α-Glucosidase Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 212. Europe α-Glucosidase Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 213. Europe α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 214. Europe α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 215. Europe α-Glucosidase Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 216. Europe α-Glucosidase Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 217. Europe α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 218. Europe α-Glucosidase Inhibitors Sales by Country (2027-2032) & (K Units) Table 219. Europe α-Glucosidase Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 220. Europe α-Glucosidase Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 221. Germany α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 222. France α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 223. U.K. α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 224. Italy α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 225. Netherlands α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 226. Nordic Countries α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 227. China α-Glucosidase Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 228. China α-Glucosidase Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 229. China α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 230. China α-Glucosidase Inhibitors Sales by Type (2027-2032) & (K Units) Table 231. China α-Glucosidase Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 232. China α-Glucosidase Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 233. China α-Glucosidase Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 234. China α-Glucosidase Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 235. China α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 236. China α-Glucosidase Inhibitors Sales by Application (2027-2032) & (K Units) Table 237. China α-Glucosidase Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 238. China α-Glucosidase Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 239. Asia α-Glucosidase Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 240. Asia α-Glucosidase Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 241. Asia α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 242. Asia α-Glucosidase Inhibitors Sales by Type (2027-2032) & (K Units) Table 243. Asia α-Glucosidase Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 244. Asia α-Glucosidase Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 245. Asia α-Glucosidase Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 246. Asia α-Glucosidase Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 247. Asia α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 248. Asia α-Glucosidase Inhibitors Sales by Application (2027-2032) & (K Units) Table 249. Asia α-Glucosidase Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 250. Asia α-Glucosidase Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 251. Asia α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 252. Asia α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 253. Asia α-Glucosidase Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 254. Asia α-Glucosidase Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 255. Asia α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 256. Asia α-Glucosidase Inhibitors Sales by Country (2027-2032) & (K Units) Table 257. Asia α-Glucosidase Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 258. Asia α-Glucosidase Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 259. Japan α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 260. South Korea α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 261. India α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 262. Australia α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 263. China Taiwan α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 264. Southeast Asia α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 265. SAMEA α-Glucosidase Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 266. SAMEA α-Glucosidase Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 267. SAMEA α-Glucosidase Inhibitors Sales by Type (2021-2026) & (K Units) Table 268. SAMEA α-Glucosidase Inhibitors Sales by Type (2027-2032) & (K Units) Table 269. SAMEA α-Glucosidase Inhibitors Sales Price by Type (2021-2026) & (US$/Unit) Table 270. SAMEA α-Glucosidase Inhibitors Sales Price by Type (2027-2032) & (US$/Unit) Table 271. SAMEA α-Glucosidase Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 272. SAMEA α-Glucosidase Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 273. SAMEA α-Glucosidase Inhibitors Sales by Application (2021-2026) & (K Units) Table 274. SAMEA α-Glucosidase Inhibitors Sales by Application (2027-2032) & (K Units) Table 275. SAMEA α-Glucosidase Inhibitors Sales Price by Application (2021-2026) & (US$/Unit) Table 276. SAMEA α-Glucosidase Inhibitors Sales Price by Application (2027-2032) & (US$/Unit) Table 277. SAMEA α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 278. SAMEA α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 279. SAMEA α-Glucosidase Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 280. SAMEA α-Glucosidase Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 281. SAMEA α-Glucosidase Inhibitors Sales by Country (2021-2026) & (K Units) Table 282. SAMEA α-Glucosidase Inhibitors Sales by Country (2027-2032) & (K Units) Table 283. SAMEA α-Glucosidase Inhibitors Sales Price by Country (2021-2026) & (US$/Unit) Table 284. SAMEA α-Glucosidase Inhibitors Sales Price by Country (2027-2032) & (US$/Unit) Table 285. Brazil α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 286. Argentina α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 287. Chile α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 288. Colombia α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 289. Peru α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 290. Saudi Arabia α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 291. Israel α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 292. UAE α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 293. Turkey α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 294. Iran α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 295. Egypt α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Table 296. Key Raw Materials Table 297. Raw Materials Key Suppliers Table 298. α-Glucosidase Inhibitors Distributors List Table 299. α-Glucosidase Inhibitors Customers List Table 300. Research Programs/Design for This Report Table 301. Authors List of This Report Table 302. Secondary Sources Table 303. Primary Sources List of Figures Figure 1. α-Glucosidase Inhibitors Image Figure 2. Global α-Glucosidase Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global α-Glucosidase Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. Acarbose Image Figure 5. Voglibose Image Figure 6. Miglitol Image Figure 7. Other Image Figure 8. Global α-Glucosidase Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global α-Glucosidase Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital and Clinic Image Figure 11. Pharmacy Image Figure 12. Other Image Figure 13. Global α-Glucosidase Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global α-Glucosidase Inhibitors Revenue (2021-2032) & (US$ Million) Figure 15. Global α-Glucosidase Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global α-Glucosidase Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global α-Glucosidase Inhibitors Revenue Market Share by Region (2021-2032) Figure 18. Global α-Glucosidase Inhibitors Sales (2021-2032) & (K Units) Figure 19. Global α-Glucosidase Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global α-Glucosidase Inhibitors Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico α-Glucosidase Inhibitors Sales YoY (2021-2032) & (K Units) Figure 22. Europe α-Glucosidase Inhibitors Sales YoY (2021-2032) & (K Units) Figure 23. China α-Glucosidase Inhibitors Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) α-Glucosidase Inhibitors Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa α-Glucosidase Inhibitors Sales YoY (2021-2032) & (K Units) Figure 26. Global α-Glucosidase Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global α-Glucosidase Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global α-Glucosidase Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global α-Glucosidase Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global α-Glucosidase Inhibitors Revenue Market Share by Type (2021-2032) Figure 32. Global α-Glucosidase Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global α-Glucosidase Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global α-Glucosidase Inhibitors Sales Market Share by Type (2021-2032) Figure 35. Global α-Glucosidase Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global α-Glucosidase Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global α-Glucosidase Inhibitors Revenue Market Share by Application (2021-2032) Figure 38. Global α-Glucosidase Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global α-Glucosidase Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global α-Glucosidase Inhibitors Sales Market Share by Application (2021-2032) Figure 41. North America α-Glucosidase Inhibitors Revenue Share by Type (2021-2032) Figure 42. North America α-Glucosidase Inhibitors Sales Share by Type (2021-2032) Figure 43. North America α-Glucosidase Inhibitors Revenue Share by Application (2021-2032) Figure 44. North America α-Glucosidase Inhibitors Sales Share by Application (2021-2032) Figure 45. North America α-Glucosidase Inhibitors Revenue Share by Country (2021-2032) Figure 46. North America α-Glucosidase Inhibitors Sales Share by Country (2021-2032) Figure 47. Europe α-Glucosidase Inhibitors Revenue Share by Type (2021-2032) Figure 48. Europe α-Glucosidase Inhibitors Sales Share by Type (2021-2032) Figure 49. Europe α-Glucosidase Inhibitors Revenue Share by Application (2021-2032) Figure 50. Europe α-Glucosidase Inhibitors Sales Share by Application (2021-2032) Figure 51. Europe α-Glucosidase Inhibitors Revenue Share by Country (2021-2032) Figure 52. Europe α-Glucosidase Inhibitors Sales Share by Country (2021-2032) Figure 53. China α-Glucosidase Inhibitors Revenue Share by Type (2021-2032) Figure 54. China α-Glucosidase Inhibitors Sales Share by Type (2021-2032) Figure 55. China α-Glucosidase Inhibitors Revenue Share by Application (2021-2032) Figure 56. China α-Glucosidase Inhibitors Sales Share by Application (2021-2032) Figure 57. Asia α-Glucosidase Inhibitors Revenue Share by Type (2021-2032) Figure 58. Asia α-Glucosidase Inhibitors Sales Share by Type (2021-2032) Figure 59. Asia α-Glucosidase Inhibitors Revenue Share by Application (2021-2032) Figure 60. Asia α-Glucosidase Inhibitors Sales Share by Application (2021-2032) Figure 61. Asia α-Glucosidase Inhibitors Revenue Share by Country (2021-2032) Figure 62. Asia α-Glucosidase Inhibitors Sales Share by Country (2021-2032) Figure 63. SAMEA α-Glucosidase Inhibitors Revenue Share by Type (2021-2032) Figure 64. SAMEA α-Glucosidase Inhibitors Sales Share by Type (2021-2032) Figure 65. SAMEA α-Glucosidase Inhibitors Revenue Share by Application (2021-2032) Figure 66. SAMEA α-Glucosidase Inhibitors Sales Share by Application (2021-2032) Figure 67. SAMEA α-Glucosidase Inhibitors Revenue Share by Country (2021-2032) Figure 68. SAMEA α-Glucosidase Inhibitors Sales Share by Country (2021-2032) Figure 69. α-Glucosidase Inhibitors Value Chain Figure 70. Manufacturing Cost Structure Figure 71. α-Glucosidase Inhibitors Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Acarbose
  • Voglibose
  • Miglitol
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Bluepharma
  • Glenmark Pharma
  • Lunan Pharma
  • Lupin Pharma
  • Strides Pharma
  • Bayer
  • Beijing SL Pharmaceutical
  • Cisen Pharmaceutical
  • Hangzhou East China Pharmaceutical
  • Pfizer
  • Jinri Pharmaceutical (China)
  • Livzon Pharm
  • Luye Pharma
  • Nanjing Hicin Pharmaceutical
  • Shandong New Time Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Weiao Pharmaceutical (Sichuan)
  • Sun Pharmaceutical
  • SUN Pharma
  • Takeda
  • YaoPharma
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Jingxin Pharmaceutical
  • Zhejiang Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 α-Glucosidase Inhibitors Market by Type
  3. 1.2.1 Global α-Glucosidase Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Acarbose
  5. 1.2.3 Voglibose
  6. 1.2.4 Miglitol
  7. 1.2.5 Other
  8. 1.3 α-Glucosidase Inhibitors Market by Application
  9. 1.3.1 Global α-Glucosidase Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital and Clinic
  11. 1.3.3 Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 α-Glucosidase Inhibitors Market Dynamics
  1. 2.1 α-Glucosidase Inhibitors Industry Trends
  2. 2.2 α-Glucosidase Inhibitors Industry Drivers
  3. 2.3 α-Glucosidase Inhibitors Industry Opportunities and Challenges
  4. 2.4 α-Glucosidase Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global α-Glucosidase Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global α-Glucosidase Inhibitors Revenue by Region
  3. 3.2.1 Global α-Glucosidase Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global α-Glucosidase Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global α-Glucosidase Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global α-Glucosidase Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global α-Glucosidase Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global α-Glucosidase Inhibitors Sales by Region
  9. 3.4.1 Global α-Glucosidase Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global α-Glucosidase Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global α-Glucosidase Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global α-Glucosidase Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global α-Glucosidase Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global α-Glucosidase Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global α-Glucosidase Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global α-Glucosidase Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global α-Glucosidase Inhibitors Sales by Manufacturers
  6. 4.2.1 Global α-Glucosidase Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global α-Glucosidase Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global α-Glucosidase Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global α-Glucosidase Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global α-Glucosidase Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global α-Glucosidase Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global α-Glucosidase Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global α-Glucosidase Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global α-Glucosidase Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 α-Glucosidase Inhibitors Tier 1, Tier 2, and Tier 3
5 α-Glucosidase Inhibitors Market by Type
  1. 5.1 Global α-Glucosidase Inhibitors Revenue by Type
  2. 5.1.1 Global α-Glucosidase Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global α-Glucosidase Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global α-Glucosidase Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global α-Glucosidase Inhibitors Sales by Type
  6. 5.2.1 Global α-Glucosidase Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global α-Glucosidase Inhibitors Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global α-Glucosidase Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global α-Glucosidase Inhibitors Price by Type
6 α-Glucosidase Inhibitors Market by Application
  1. 6.1 Global α-Glucosidase Inhibitors Revenue by Application
  2. 6.1.1 Global α-Glucosidase Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global α-Glucosidase Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global α-Glucosidase Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global α-Glucosidase Inhibitors Sales by Application
  6. 6.2.1 Global α-Glucosidase Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global α-Glucosidase Inhibitors Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global α-Glucosidase Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global α-Glucosidase Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Bluepharma
  2. 7.1.1 Bluepharma Company Information
  3. 7.1.2 Bluepharma Business Overview
  4. 7.1.3 Bluepharma α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bluepharma α-Glucosidase Inhibitors Product Portfolio
  6. 7.1.5 Bluepharma Recent Developments
  7. 7.2 Glenmark Pharma
  8. 7.2.1 Glenmark Pharma Company Information
  9. 7.2.2 Glenmark Pharma Business Overview
  10. 7.2.3 Glenmark Pharma α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Glenmark Pharma α-Glucosidase Inhibitors Product Portfolio
  12. 7.2.5 Glenmark Pharma Recent Developments
  13. 7.3 Lunan Pharma
  14. 7.3.1 Lunan Pharma Company Information
  15. 7.3.2 Lunan Pharma Business Overview
  16. 7.3.3 Lunan Pharma α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Lunan Pharma α-Glucosidase Inhibitors Product Portfolio
  18. 7.3.5 Lunan Pharma Recent Developments
  19. 7.4 Lupin Pharma
  20. 7.4.1 Lupin Pharma Company Information
  21. 7.4.2 Lupin Pharma Business Overview
  22. 7.4.3 Lupin Pharma α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Lupin Pharma α-Glucosidase Inhibitors Product Portfolio
  24. 7.4.5 Lupin Pharma Recent Developments
  25. 7.5 Strides Pharma
  26. 7.5.1 Strides Pharma Company Information
  27. 7.5.2 Strides Pharma Business Overview
  28. 7.5.3 Strides Pharma α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Strides Pharma α-Glucosidase Inhibitors Product Portfolio
  30. 7.5.5 Strides Pharma Recent Developments
  31. 7.6 Bayer
  32. 7.6.1 Bayer Company Information
  33. 7.6.2 Bayer Business Overview
  34. 7.6.3 Bayer α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Bayer α-Glucosidase Inhibitors Product Portfolio
  36. 7.6.5 Bayer Recent Developments
  37. 7.7 Beijing SL Pharmaceutical
  38. 7.7.1 Beijing SL Pharmaceutical Company Information
  39. 7.7.2 Beijing SL Pharmaceutical Business Overview
  40. 7.7.3 Beijing SL Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Beijing SL Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  42. 7.7.5 Beijing SL Pharmaceutical Recent Developments
  43. 7.8 Cisen Pharmaceutical
  44. 7.8.1 Cisen Pharmaceutical Company Information
  45. 7.8.2 Cisen Pharmaceutical Business Overview
  46. 7.8.3 Cisen Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Cisen Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  48. 7.8.5 Cisen Pharmaceutical Recent Developments
  49. 7.9 Hangzhou East China Pharmaceutical
  50. 7.9.1 Hangzhou East China Pharmaceutical Company Information
  51. 7.9.2 Hangzhou East China Pharmaceutical Business Overview
  52. 7.9.3 Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Hangzhou East China Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  54. 7.9.5 Hangzhou East China Pharmaceutical Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer α-Glucosidase Inhibitors Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 Jinri Pharmaceutical (China)
  62. 7.11.1 Jinri Pharmaceutical (China) Company Information
  63. 7.11.2 Jinri Pharmaceutical (China) Business Overview
  64. 7.11.3 Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Jinri Pharmaceutical (China) α-Glucosidase Inhibitors Product Portfolio
  66. 7.11.5 Jinri Pharmaceutical (China) Recent Developments
  67. 7.12 Livzon Pharm
  68. 7.12.1 Livzon Pharm Company Information
  69. 7.12.2 Livzon Pharm Business Overview
  70. 7.12.3 Livzon Pharm α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Livzon Pharm α-Glucosidase Inhibitors Product Portfolio
  72. 7.12.5 Livzon Pharm Recent Developments
  73. 7.13 Luye Pharma
  74. 7.13.1 Luye Pharma Company Information
  75. 7.13.2 Luye Pharma Business Overview
  76. 7.13.3 Luye Pharma α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Luye Pharma α-Glucosidase Inhibitors Product Portfolio
  78. 7.13.5 Luye Pharma Recent Developments
  79. 7.14 Nanjing Hicin Pharmaceutical
  80. 7.14.1 Nanjing Hicin Pharmaceutical Company Information
  81. 7.14.2 Nanjing Hicin Pharmaceutical Business Overview
  82. 7.14.3 Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Nanjing Hicin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  84. 7.14.5 Nanjing Hicin Pharmaceutical Recent Developments
  85. 7.15 Shandong New Time Pharmaceutical
  86. 7.15.1 Shandong New Time Pharmaceutical Company Information
  87. 7.15.2 Shandong New Time Pharmaceutical Business Overview
  88. 7.15.3 Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Shandong New Time Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  90. 7.15.5 Shandong New Time Pharmaceutical Recent Developments
  91. 7.16 CSPC Ouyi Pharmaceutical
  92. 7.16.1 CSPC Ouyi Pharmaceutical Company Information
  93. 7.16.2 CSPC Ouyi Pharmaceutical Business Overview
  94. 7.16.3 CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 CSPC Ouyi Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  96. 7.16.5 CSPC Ouyi Pharmaceutical Recent Developments
  97. 7.17 Weiao Pharmaceutical (Sichuan)
  98. 7.17.1 Weiao Pharmaceutical (Sichuan) Company Information
  99. 7.17.2 Weiao Pharmaceutical (Sichuan) Business Overview
  100. 7.17.3 Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Weiao Pharmaceutical (Sichuan) α-Glucosidase Inhibitors Product Portfolio
  102. 7.17.5 Weiao Pharmaceutical (Sichuan) Recent Developments
  103. 7.18 Sun Pharmaceutical
  104. 7.18.1 Sun Pharmaceutical Company Information
  105. 7.18.2 Sun Pharmaceutical Business Overview
  106. 7.18.3 Sun Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Sun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  108. 7.18.5 Sun Pharmaceutical Recent Developments
  109. 7.19 SUN Pharma
  110. 7.19.1 SUN Pharma Company Information
  111. 7.19.2 SUN Pharma Business Overview
  112. 7.19.3 SUN Pharma α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 SUN Pharma α-Glucosidase Inhibitors Product Portfolio
  114. 7.19.5 SUN Pharma Recent Developments
  115. 7.20 Takeda
  116. 7.20.1 Takeda Company Information
  117. 7.20.2 Takeda Business Overview
  118. 7.20.3 Takeda α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Takeda α-Glucosidase Inhibitors Product Portfolio
  120. 7.20.5 Takeda Recent Developments
  121. 7.21 YaoPharma
  122. 7.21.1 YaoPharma Company Information
  123. 7.21.2 YaoPharma Business Overview
  124. 7.21.3 YaoPharma α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 YaoPharma α-Glucosidase Inhibitors Product Portfolio
  126. 7.21.5 YaoPharma Recent Developments
  127. 7.22 Zhejiang Hisun Pharmaceutical
  128. 7.22.1 Zhejiang Hisun Pharmaceutical Company Information
  129. 7.22.2 Zhejiang Hisun Pharmaceutical Business Overview
  130. 7.22.3 Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Zhejiang Hisun Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  132. 7.22.5 Zhejiang Hisun Pharmaceutical Recent Developments
  133. 7.23 Zhejiang Jingxin Pharmaceutical
  134. 7.23.1 Zhejiang Jingxin Pharmaceutical Company Information
  135. 7.23.2 Zhejiang Jingxin Pharmaceutical Business Overview
  136. 7.23.3 Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Zhejiang Jingxin Pharmaceutical α-Glucosidase Inhibitors Product Portfolio
  138. 7.23.5 Zhejiang Jingxin Pharmaceutical Recent Developments
  139. 7.24 Zhejiang Medicine
  140. 7.24.1 Zhejiang Medicine Company Information
  141. 7.24.2 Zhejiang Medicine Business Overview
  142. 7.24.3 Zhejiang Medicine α-Glucosidase Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Zhejiang Medicine α-Glucosidase Inhibitors Product Portfolio
  144. 7.24.5 Zhejiang Medicine Recent Developments
8 North America
  1. 8.1 North America α-Glucosidase Inhibitors Market Size by Type
  2. 8.1.1 North America α-Glucosidase Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America α-Glucosidase Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America α-Glucosidase Inhibitors Price by Type (2021-2032)
  5. 8.2 North America α-Glucosidase Inhibitors Market Size by Application
  6. 8.2.1 North America α-Glucosidase Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America α-Glucosidase Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America α-Glucosidase Inhibitors Price by Application (2021-2032)
  9. 8.3 North America α-Glucosidase Inhibitors Market Size by Country
  10. 8.3.1 North America α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America α-Glucosidase Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America α-Glucosidase Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe α-Glucosidase Inhibitors Market Size by Type
  2. 9.1.1 Europe α-Glucosidase Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe α-Glucosidase Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe α-Glucosidase Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe α-Glucosidase Inhibitors Market Size by Application
  6. 9.2.1 Europe α-Glucosidase Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe α-Glucosidase Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe α-Glucosidase Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe α-Glucosidase Inhibitors Market Size by Country
  10. 9.3.1 Europe α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe α-Glucosidase Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe α-Glucosidase Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China α-Glucosidase Inhibitors Market Size by Type
  2. 10.1.1 China α-Glucosidase Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China α-Glucosidase Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China α-Glucosidase Inhibitors Price by Type (2021-2032)
  5. 10.2 China α-Glucosidase Inhibitors Market Size by Application
  6. 10.2.1 China α-Glucosidase Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China α-Glucosidase Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China α-Glucosidase Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia α-Glucosidase Inhibitors Market Size by Type
  2. 11.1.1 Asia α-Glucosidase Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia α-Glucosidase Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia α-Glucosidase Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia α-Glucosidase Inhibitors Market Size by Application
  6. 11.2.1 Asia α-Glucosidase Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia α-Glucosidase Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia α-Glucosidase Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia α-Glucosidase Inhibitors Market Size by Country
  10. 11.3.1 Asia α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia α-Glucosidase Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia α-Glucosidase Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA α-Glucosidase Inhibitors Market Size by Type
  2. 12.1.1 SAMEA α-Glucosidase Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA α-Glucosidase Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA α-Glucosidase Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA α-Glucosidase Inhibitors Market Size by Application
  6. 12.2.1 SAMEA α-Glucosidase Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA α-Glucosidase Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA α-Glucosidase Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA α-Glucosidase Inhibitors Market Size by Country
  10. 12.3.1 SAMEA α-Glucosidase Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA α-Glucosidase Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA α-Glucosidase Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 α-Glucosidase Inhibitors Value Chain Analysis
  2. 13.1.1 α-Glucosidase Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 α-Glucosidase Inhibitors Production Mode & Process
  6. 13.2 α-Glucosidase Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 α-Glucosidase Inhibitors Distributors
  9. 13.2.3 α-Glucosidase Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst